Early Bird discounts:
Register early to save €500 for the Individual ticket, €600 per person for 2-3 Delegates, €700 per person for 4+ delegates from the same company until February 22nd.
The recent years have witnessed major growth in the inhaled drugs market driven by rising prevalence of chronic pulmonary diseases, the evolution of inhaled therapies and technological advancements in device development. Challenges still remain to ensure safe and efficient respiratory drug delivery - including device and drug integration, particle engineering and formulation technologies, clinical studies and regulatory pathways. Our meeting facilitates hands-on experience sharing of successful development of inhaled drug products for enhanced patient care.
The call for speakers is open now.
Please find below the tentative schedule. Speaking sessions will be grouped according to similar themes into blocks and published upon finalizing the agenda, so please check back!
07:30 Registration and Welcome Coffee
08:15 Opening Address from the Chairman
08:25 Clash of the cultures: Requirements for inhalation bioequivalence – contrasts between US, EU, Australia, Japan, Brazil.
09:50 Speed Networking
09:40 Applying the TRIZ Methodology to Medical Device Innovations.
10:15 The pMDI, issues, opportunities and the future for the current generation of products.
Director, Paul Johnson Consulting Limited, Cambridge, UK
10:50 Morning coffee and networking break
11:20 Development of a generic triple combination product – hurdles and opportunities.
11:55 Re-thinking the opportunities for nebulised drugs.
Dr. John N Pritchard
Independent Business Owner, Inspiring Strategies, Leicester, United Kingdom
12:30 Business lunch
13:30 MDI IVIVR.
14:05 Development of an in vitro high content analysis screen to assess new compounds and formulations for adverse alveolar macrophage effects.
14:40 Afternoon coffee and networking break
15:10 Considering Human Factors in Inhaled Drug Products..
15:45 TO BE ANNOUNCED.
16:20 Probing the Aerodynamic Particle Size Distribution of Dry Powder Inhaler Combination Products Foster® NEXThaler® and Seretide® Diskus® using Single Particle Aerosol Mass Spectrometry (SPAMS).
16:55 Panel Discussion
17:30 Chairman’s closing remarks and end of day one
19:00 Business dinner
08:00 Registration and Welcome Coffee
08:40 Opening Address from the Chairman
08:50 Dosing and process control technologies to cover the wide variety of Dry Powder Inhalers.
Dosing systems to fill DPI have to be adapted to the type of containment to be filled, the dosing range and the powder properties.
The functional principle of the different technologies, the integration into production machines and the requirements regarding powder properties will be described.
To mitigate the risk for under-filling during production, not being detected by statistical in-process controls, systems for the 100% in-line verification of fill weights have been developed.
Three different approaches will be presented.
09:25 Engineering particles to deliver high dosed and sensitive drugs to the lung using standard inhaler systems.
10:00 Experimental investigation of inhaled nanoparticles in the respiratory tract.
His presentation provides an overview on experimental studies of the deposition of inhaled nanoparticles in the respiratory tract.
It also describes some possible benefits of using nanoparticles in medical inhalation applications.
Finally, a new method is presented for detection of respiratory disease based on the deposition of nanoparticles.
10:35 Morning coffee and networking break
11:05 Nano-structured Microparticles for pulmonary application.
11:40 Rethinking DPI packaging environment. Using integrated three-phase Activ-polymer to control moisture ingress and improve performance.
12:15 Business lunch
13:15 Using mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery.
13:50 Material selection for OINDPs (orally inhaled and nasal drug products).
14:25 New lung disposition software: Derisking inhaled product changes using predictive models.
15:00 Afternoon coffee and networking break
15:30 The compendium case history of inhalation APIs: key topics form several developments..
16:05 Inhaled antimicrobials: Current strategies and future challenges.
16:40 Panel Discussion
17:20 Chairman’s closing remarks and end of summit
To register to the summit as Delegate, Exhibitor or Sponsor, please provide the details below. Once the form is submitted, we will send you the official confirmation and the invoice for payment. In case of doubt, contact us at email@example.com
Please fill in the details below to request your copy of the latest summit agenda and event details.
Documentation Package for € 499 includes presentation slide decks and the delegate contact list.*
chaired a panel discussion on the digitisation of clinical trials and next gen injectable devices, with speakers from Novartis, Roche, Janssen, Sanofi, SHL Group and Corvus Device.